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ABSTRACT 53 
The Lesotho guidelines for the management of drug-resistant TB recommend initiation of 54 
patients diagnosed with rifampicin resistant (RR)-TB using Xpert MTB/RIF assay on an empiric 55 
regimen while awaiting for confirmation of RR-TB and a complete drug susceptibility test result. 56 
Review of diagnostic records between 2014 and 2016 identified 518 patients with RR-TB. Only 57 
314 (60.6%) patients could be linked to treatment records at the Lesotho MDR hospital; 291 58 
(92.7%) were eligible for analysis. The median treatment delay from the availability of Xpert 59 
MTB/RIF assay result was 12 days (IQR 7-19). Only 32% (101) of patients had a documented 60 
first-line drug resistant test. MDR-TB was detected in 56.4% of patients while 33.7% of patients 61 
had rifampicin mono-resistance. Only 7.4% of patients assessed for second-line resistance had 62 
a positive result (resistance to a fluoroquinolone). Treatment success was 72%, death rate was 63 
26.9%, loss to follow up was 0.7%, and 0.4 % failed treatment. Death was associated with 64 
positive or unavailable sputum smear at the end of first month of treatment (Fisher exact 65 
p<0.001) and older age (p=0.007). Urgent attention needs to be given to link patients with RR-66 
TB to care - a worldwide problem. The association of death rate with positive sputum smear at 67 
the end of the first month of treatment should trigger individualization of treatment. 68 
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INTRODUCTION 69 
The tuberculosis (TB) epidemic remains a worldwide public health threat affecting mainly low- 70 
and middle-income countries. In 2017, an estimated 10 million people developed the disease 71 
and 16% (1.6 million) of those who fell ill with TB lost their lives1.  72 
Prevention of new infections and substantial reduction in TB-related deaths are critical in the 73 
process of controlling the TB epidemic. The World Health Organization (WHO) End TB Strategy 74 
aims to reduce the number of new cases of TB by 90% and the number of TB-related death by 75 
95% by 2035 compared with 20152,3. These End TB targets together with the Sustainable 76 
Development Goals are endorsed by the WHO 1. However, TB control is constantly challenged 77 
with the emergence of drug resistance that complicates diagnosis and requires complex 78 
treatment with highly toxic drugs1-5. 79 
TB is caused by the pathogen Mycobacterium tuberculosis (MTB) which, in most cases, is 80 
susceptible to rifampicin, isoniazid, ethambutol and pyrazinamide (pan-susceptible). Drug-81 
resistance emerges as a result of mutations in MTB’s genes.6. The mutations develop as a 82 
result of improper use of anti-TB drugs (acquired resistance) or through transmission of an 83 
already resistant strain of M. tuberculosis (primary resistance)6. Molecular epidemiological 84 
studies and modeling suggest that transmission is the primary mechanism whereby the drug 85 
resistant TB epidemic is globally perpetuated6-9.  86 
In 2017, the WHO estimated the number of rifampicin resistant TB cases to 558 000 (RR-TB), 87 
which is a slight decrease compared to the 600 000 cases estimated globally in 2016. China, 88 
India and Russia contribute approximate 47% of RR-TB cases1. In total, 30 high burden drug 89 
resistant TB countries have been identified by the WHO, of which eight are in Africa1. In Lesotho 90 
(one of the high burden TB countries), 4.8% of new TB cases and 14% of previously treated 91 
cases are estimated to have drug-resistant TB (resistance to at least one of the Tuberculosis 92 
drugs)1. The Lesotho National Tuberculosis program reported 152 cases of drug resistant TB in 93 
2014, 209 cases in 2015 and 245 cases in 2016. Between January 2014 and December 2016, 94 
more than two thirds of patients diagnosed with drug-resistant TB were HIV positive new cases, 95 
while approximately 30% of these patients had received prior TB treatment (retreatment 96 
cases)1,10-12. 97 
To address the increasing drug-resistant TB epidemic, the Lesotho National Tuberculosis 98 
program recommends the use of the Xpert MTB/RIF assay as the first line test for the diagnosis 99 
of pulmonary TB. Since 2015, all the government and Christian Health Association of Lesotho’s 100 
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hospitals were capacitated to provide diagnosis using the Xpert MTB/RIF assay. The 101 
implementation of GeneXpert has aimed to improve TB case detection due to the high accuracy 102 
of the test, reduce the time to TB diagnosis and treatment initiation due to the rapidity of the 103 
test, and improve TB treatment outcomes by earlier identification of patients with RR-TB13,14. 104 
The current Lesotho National Guidelines for Tuberculosis recommend initiation of all patients 105 
diagnosed with RR-TB [using either the Xpert MTB/RIF assay or any other method of diagnosis 106 
(Line probe assay, culture) on an empiric standard drug resistant TB treatment regimen. This 107 
empiric regimen may be adjusted based on subsequent drug susceptibility test (DST) results15. 108 
Despite the implementation of the GeneXpert in Lesotho, Tuberculosis case detection remains 109 
low (48%). Furthermore, the impact of the Xpert MTB/RIF assay on initiation of multi-drug 110 
resistant (MDR)-TB (resistance to at least rifampicin and isoniazid) treatment remains unknown. 111 
Studies from South Africa reported substantial delays for treatment initiation and high rates of 112 
suboptimal treatment for patients diagnosed with RR-TB when initiating treatment based solely 113 
on the Xpert MTB/RIF result1,13,16-18. 114 
In this study, we aimed to determine the proportion of patients with RR-TB linked to MDR-TB 115 
treatment, turnaround time for treatment initiation, factors associated with delays, and to assess 116 
treatment outcomes for patients diagnosed with RR-TB using the Xpert MTB/RIF assay.  117 
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RESULTS  118 
Participant characteristics and RR-TB distribution 119 
We visited 19 GeneXpert facilities throughout Lesotho and were able to identify 527 patients 120 
diagnosed with RR-TB between January 2014 and December 2016 using the Xpert MTB/RIF 121 
assay (Figure 1). Nine patients were excluded because they were either under the age of 18 122 
years or had missing dates of birth. 123 
Of the 518 patients diagnosed with RR-TB, 314 (60.6%) were successfully matched to Lesotho 124 
MDR Hospital records (Table 1). The remaining 204 (39.4%) patients could not be matched. 125 
The mean age between matched and unmatched patients were similar (mean difference 0 .79, 126 
95% CI (1.57 - 3.15)), there were no difference in gender distribution (X2=1.51, p=0.22) or 127 
patient distribution per district (X2=11.70 p=0.23) between the two groups.  128 
Table 1 gives the primary characteristics of all the study participants. Fifty-seven percent were 129 
new cases, 78% were HIV positive and 82% of those with an HIV positive status were already 130 
on antiretroviral treatment at the time of treatment initiation. Sixty-one percent were male with 131 
most patients being between 31 to 40 years (32.8%). Mean weight before treatment was 53. 0 132 
kg (95% CI 51.5-54.5) and after treatment 60.1kg (95% CI 58.5-61.8).  A history of working in a 133 
South African mine was the most common occupation (19%).  134 
Treatment delay and associated factors 135 
Of the 314 study patients with matched hospital records, 291 (92.67%) were eligible for 136 
analysis. We excluded 23 patients with missing date of treatment initiation or who were already 137 
on treatment for drug resistant TB when the diagnosis of RR-TB was made at the visited 138 
GeneXpert facility. The overall median time to treatment initiation was 12 days (IQR 7-19) 139 
(Table 2). Patients from Mokhotlong district had the shortest delay in treatment initiation, 6.5 140 
days (IQR 5-8) while patients from Thaba Tseka had the longest delay, 60 days (IQR 22-70). 141 
There were no associations between time to treatment initiation and gender (Mann-Whitney, 142 
p=0.94), age group (Kruskal Wallis, X2=2.39, 4 d.f., p=0.66), HIV status (Mann-Whitney, 143 
p=0.81), history of previous TB (Kruskal Wallis, X2=0.97, 2 d.f., p=0.62), or distance between 144 
GeneXpert facility and MDR hospital (Spearman’s rho= -0.14, p=0.02).  145 
Of the patients seen at the MDR hospital, only 101 (32%) were further assessed for first-line 146 
drug susceptibility, while 81 (26%) had a specimen sent for second-line DST (Table 3). MDR-TB 147 
was diagnosed in 57 (56.4%) and rifampicin mono-resistant TB in 34 (33.7%) patients. The 148 
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proportion of patients with resistance to second-line anti-TB drugs cannot be accurately 149 
determine due to the high number for culture negative results (92.5%).  150 
Treatment outcomes and associated factors 151 
For treatment outcomes, we only analyzed data on patients who had a positive delay of 152 
treatment initiation because we were not sure of the diagnostic method used initially for these 153 
patients. Of the 291 patients with positive delay, only 268 (92.1%) were eligible for treatment 154 
outcome analysis. We excluded five patients because of missing data on outcomes, four 155 
because they were still receiving treatment at the time of data collection and 14 were not 156 
evaluated. Overall the treatment success rate was 72% (193) and the death rate 26.9% (72). 157 
Only two patients were lost to follow up (0.7%), and one patient had treatment failure (0.4%).  158 
We assessed factors such as age, gender, weight before treatment, HIV status, previous history 159 
of TB and sputum smear result after one month of treatment for their association with the 160 
treatment outcomes. There was no evidence of association between HIV status and treatment 161 
outcome (Fisher’s exact p=0.47), weight before treatment and treatment outcome (ANOVA F (2, 162 
192) =1.11, p=0.33), history of previous TB and treatment outcome (Fisher’s exact p= 0.54) 163 
and, gender and treatment outcome (Fisher’s exact, p=0.50). However, our study showed an 164 
association between sputum smear positivity after one month of treatment and treatment 165 
outcome as well as between age and treatment outcome. Patients with positive sputum smear 166 
after one month of treatment and those with no sputum smear result were more likely to die 167 
when compared to patients with a negative sputum smear after one month of treatment 168 
(Fisher’s exact, p<0.001). Mean age between the three categories (treatment success, death 169 
and other poor outcomes) was different (ANOVA F (2,279) = 5.17, p=0.0063) with older patients 170 
more likely to die compared to younger patients (Mean difference in age between those who 171 
were cured and those who died was 5.56 years, Bonferroni adjusted p=0.007). There was no 172 
difference in age between patients with positive, negative, and unavailable sputum results at the 173 
end of month one (ANOVA F (2,28) =1.96, p=0.14). This indicates minimal risk of confounding 174 
between these two variables for their association with treatment outcomes.  175 
The majority of patients were started on isoniazid, kanamycin, levofloxacin, prothionamide, 176 
cycloserine and para-amino salicylic acid as initial treatment regimen. We could not assess the 177 
association between the initial treatment regimen and treatment outcomes because some of the 178 
patients had their regimen adjusted after DST and/or medication side effects were reported. 179 
Less than 10%of patients had at least one of the new TB drugs (delaminid, bedaquiline) in their 180 
treatment regimen.  181 
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DISCUSSION 182 
With this study we were able to determine the proportion of RR-TB cases linked to care, the 183 
turnaround time to treatment initiation, the implementation of confirmatory phenotypic DST and 184 
factors influencing treatment outcomes for patients in the Kingdom of Lesotho. 185 
Our study is inclusive of patients coming from both urban and rural settings and in a context of 186 
centralized care where patients can only be initiated on treatment at one Hospital in Maseru, the 187 
capital of Lesotho. Only 60% of RR-TB cases could be linked to care, implying that the 188 
remaining 40% of cases were not on treatment, thereby possibly contributing to the 189 
transmission of drug resistant TB, or had died prior to initiating treatment or sought treatment 190 
outside of Lesotho. For those linked to care, the median time to treatment initiation was 12 days 191 
(IQR 7-19) despite the difficulty of transport in this mountainous terrain. This compares well with 192 
the median delay-time of 13 days (IQR 7-28) and 15 days (IQR 8-23) reported in Johannesburg 193 
and in the Eastern Cape of South Africa, respectively. In a Cape Town study, Cox et al. found a 194 
relatively shorter median time to treatment initiation of eight days17,18,20,21. In these studies, time 195 
to treatment initiation was measured from sputum submission at the laboratory while we 196 
measured it from the availability of a positive Xpert MTB/RIF assay result with rifampicin 197 
resistance. Given the Xpert MTB/RIF assay turnaround time, we assume that there is no 198 
significant difference between the two measurements.  199 
Surprisingly, we noted a number of patients with negative treatment delay. These patients were 200 
on treatment for drug resistant TB prior to the diagnosis of RR-TB at the GeneXpert facility22. 201 
The Lesotho Tuberculosis guidelines need to address the value of using the Xpert MTB/RIF 202 
assay to diagnose RR-TB in patients already on treatment, as the current WHO guidelines do 203 
not recommend the use of the Xpert MTB/RIF assay to monitor patients on anti-TB treatment15, 204 
22. 205 
Only 32% of patients on empiric MDR-TB treatment had a confirmatory phenotypic DST despite 206 
this being done at the Lesotho National Tuberculosis Laboratory. This implies that the vast 207 
majority of patients with RR-TB were treated blindly, which could explain the high death rate. 208 
The high proportion of rifampicin mono-resistance is similar to what has been reported in South 209 
Africa23,24 and has been linked to acquisition through malabsorption associated with HIV co-210 
infection25-27. However, we cannot exclude the possibility of ongoing transmission, as 211 
approximately 50% of patients diagnosed with RR-TB were new cases. Unfortunately, the 212 
extent of second-line resistance in RR-TB cannot be assessed from this study, as only 7% of 213 
DSTs requested gave an actionable result by demonstrating the presence of resistance to a 214 
Stellenbosch University  https://scholar.sun.ac.za
10 
 
fluoroquinolone. The yield of actionable results may be improved using a molecular DST 215 
method such as the GenoType MTBDRsl assay (second-line LPA) endorsed by the WHO28.  216 
Despite limited knowledge of the resistance profiles of the strains circulating in Lesotho, 217 
treatment success was observed in 72% of patients, death in 26.9%, loss to follow up in 0.7% 218 
and treatment failure in 0.4%. Only month one sputum smear results were strongly associated 219 
with poor treatment outcomes. Treatment success and death rates observed in our study are 220 
similar to results reported by the Lesotho National Tuberculosis program, respectively 67% and 221 
28%29. The treatment success rate is greater than the global treatment success rate of 55% 222 
reported by the 2018 Tuberculosis report and greater than the 39% reported by a study in 223 
Johannesburg, South Africa but lower compared to the global target. The death rate was higher 224 
than that reported globally (15%) and in South Africa (14%) but similar to death rates observed 225 
in Mozambique (26%)1.  226 
Data for this study was collected from routine records from the GeneXpert facilities and MDR 227 
hospital. Since routine records are not intended for research, they are not recorded 228 
systematically. This may have led to under and/or overestimation of some of our findings. Our 229 
estimate of linkage to care may be an under-representation given that patient names could have 230 
been recorded differently between the GeneXpert facility and the MDR hospital. High rate of 231 
treatment success may be due survival effect, many patients may have died before linkage to 232 
treatment and were therefor not included in our analysis. 233 
In summary, new strategies need to be implemented to increase the proportion of RR-TB cases 234 
linked to care. Such strategies may also impact on the time to MDR-TB treatment initiation to 235 
meet the Lesotho National Tuberculosis program guidelines. To further improve treatment 236 
outcomes, DST should be implemented for all patients diagnosed with RR-TB. This will also 237 
limit the selection of M. tuberculosis strains with drug resistance beyond MDR.   238 
Stellenbosch University  https://scholar.sun.ac.za
11 
 
METHODS 239 
Study design 240 
A retrospective cohort study of patients diagnosed with RR-TB using the Xpert MTB/RIF assay 241 
from the 1st of January 2014 to the 31st of December 2016 was conducted. All patients aged 18 242 
years and above, diagnosed with RR-TB, were included. 243 
Ethical approval  244 
This study was approved by the Health Research Ethics Committee at Stellenbosch University 245 
and the Lesotho Ministry of Health Research committee. The ethical approval from the Lesotho 246 
Ministry of Health was sufficient for data collection in Lesotho’s public hospitals after an 247 
arrangement with either the Hospital Medical Superintendent or the Laboratory Manager. For 248 
Christian Health Association of Lesotho (CHAL) hospitals, we obtained additional authorizations 249 
from CHAL’s executive director and from each member of CHAL’s hospital management team. 250 
For the Lesotho MDR hospital, we obtained authorization from The Lesotho Partners in Health 251 
(PIH) that run the hospital. 252 
Study sites 253 
GeneXpert facilities at hospitals in 10 districts in Lesotho [Maseru District (Queen Elisabeth II 254 
Hospital, Teba Clinic, National Tuberculosis Reference Laboratory, Scott Hospital, Saint Joseph 255 
Hospital, Lesotho MDR Hospital), Mafeteng District (Mafeteng Hospital), Mohale’s Hoek District 256 
(Ntsekhe Hospital), Quthing District (Quthing Hospital), Qacha’s Nek District (Machabeng 257 
Hospital, Tebellong Hospital), Berea District (Berea Hospital, Maluti Adventist Hospital), Leribe 258 
District (Teba clinic, Motebang Hospital), Butha Buthe District ( Butha Buthe Hospital, Seboche 259 
Hospital), Thaba Tseka District (Saint James hospital and Paray Hospital), Mokhotlong District 260 
(Mokhotlong Hospital)] were included for Xpert MTB/RIF data collection. We did not collect data 261 
from GeneXpert facilities located at Mamohau Hospital where we did not get the approval from 262 
the hospital management and at the Lesotho MDR Hospital due to time constraints. 263 
Sampling method 264 
Data were collected in two phases; the first phase consisted of diagnostic data collection done 265 
at GeneXpert facilities and the second phase consisted of clinical data collection done at the 266 
hospital where patients with drug resistant TB were treated. Most of the GeneXpert facilities 267 
used an electronic data storage system (DISA) with the exception of three centers (Queen 268 
Elisabeth II Hospital, Teba Clinic Maseru and Teba Clinic Leribe) that used manual registers. 269 
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For GeneXpert facilities using DISA, we searched for all patients with an Xpert MTB/RIF assay 270 
result and later filtered for patients in whom RR-TB was diagnosed. Patients with RR-TB were 271 
consequently included in our study if they met all study entry criteria (age 18 years and above, 272 
diagnosis of pulmonary RR-TB using Xpert MTB/RIF between January 2014 and December 273 
2016). For GeneXpert facilities using manual registers, patients were included in the study after 274 
they were identified as having RR-TB in the register. 275 
Patients diagnosed with RR-TB at the respective GeneXpert facilities were then searched for in 276 
the Lesotho MDR Hospital (Botsabelo) records as this is the only hospital in the country 277 
accredited to provide comprehensive MDR-TB treatment. Patients identified at the GeneXpert 278 
facilities had a minimum follow up time of 24 months to access treatment. For patients who were 279 
successfully matched, folders were reviewed for data collection. 280 
For patients that were matched at the hospital, we collected the following information: arrival 281 
date at hospital, initiation date of treatment, physical address, occupation, weight before 282 
treatment initiation and after treatment completion, HIV status, history of previous TB and 283 
method of diagnosis, treatment outcome of previous TB, treatment regimen of current episode 284 
of TB, sputum smear results from month 1 to month 24, first-line drug susceptibility results, 285 
second-line drug susceptibility results, treatment outcome. We were, however, unable to collect 286 
information on patients’ concurrent morbidities, treatment side effects, viral load (if HIV positive) 287 
and CD4 counts. 288 
We defined treatment delay as the interval between the date of availability of a positive Xpert 289 
MTB/RIF result (with rifampicin resistance) and the date of initiation on MDR-TB treatment. 290 
Patients with positive treatment delay are those initially diagnosed at the visited GeneXpert 291 
facility and initiated on treatment afterward while those with negative delay were patients who 292 
were already on treatment at the time of diagnosis at the GeneXpert facility. We excluded 293 
patients with negative delay in our analysis because we were not sure of the diagnostic method 294 
used for their diagnosis and because some of them had been on treatment before the period of 295 
our study. Treatment outcomes were recorded as per the WHO definitions (cure, failure, lost to 296 
follow up, completed, died, not evaluated), treatment success rate is given by the sum of cure 297 
and completed 19. Due to low numbers of observations in some categories (one for treatment 298 
failure and two for lost to follow up), we reduced the number of categories to three (treatment 299 
success, death and other poor outcomes). Distance to the MDR hospital was calculated using 300 
google map and represent the distance from the district where the patient was diagnosed RR-301 
TB to Maseru where the MDR Hospital is located. 302 
Stellenbosch University  https://scholar.sun.ac.za
13 
 
Statistical analysis  303 
Data collected were analyzed using Stata 14.0. Demographics of study participants were 304 
presented using frequency tables, mean, standard deviation and 95% confidence interval (CI) 305 
for normally distributed data or median and interquartile range for skewed data. Normally 306 
distributed data were analyzed using one-way ANOVA with post hoc Bonferroni tests. Data that 307 
were not normally distributed were analyzed using Wilcoxon Rank Sum test (Mann-Whitney), 308 
Kruskal Wallis tests and Spearman’s rank correlation. Categorical data were analyzed using Chi 309 
squared and Fisher exact tests. A p value <0.05 was considered as statically significant.  310 
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Figure Legend 398 
Figure 1: Flow diagram of patients with RR-TB included in the study 399 
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Table 1. Primary characteristics of study participants* 401 
 402 
Category   Number of participants 
(%) 
Age group (N = 314) 18-30 years 75 (23.9) 
 31-40 years 103 (32.8) 
 41-50 years 52 (16.6) 
 >50 84 (26.8) 
Gender (N = 314) Male 191 (60.8) 
 Female 123(39.2) 
Occupation (N = 314) Mine and Ex-mine 
workers 
59 (19.0) 
 Other occupations 105 (33.8) 
 No occupation 120 (38.6) 
 Unknown occupation 27 (8.7) 
 Missing 4 (1.3) 
History of previous TB (N = 
314) 
Yes 134 (42.9) 
 No 179 (57.0) 
 Unknown 1 (0.3) 
HIV status (N = 314) Positive  245 (78.0) 
 Negative 69 (22.0) 
Use of ARVs (N = 245) Yes 201 (82.0) 
 No 44 (18.0) 
Weight before treatment (kg)  
(N = 194) Mean (**SD) 
53.0 (10.3) 95% ***CI 51.5-54.5 
Weight after treatment (kg) 
(N = 194) Mean (SD) 
60.1 (11.6) 95% CI 58.5-61.8 
 403 
*For age and gender N represent the total number of patients included in the study (314), for 404 
occupation, history of TB and HIV status N is the number of patients matched at the hospital 405 
(314), for use of ARVs N is equal to the number of HIV+ patients (245). For weight N is equal to 406 
the number of patients with both pre- and post-treatment weight and with treatment outcome 407 
different from active and not evaluated. 408 
**Standard deviation 409 
***Confidence interval 410 
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Table 2. Distributions of patients diagnosed with RR-TB and median delay in initiation of MDR-TB treatment  411 
 412 
Districts 
Total  
(N = 518) 
(%) 
Total 
attending 
MDR-TB 
hospital 
(Matched) 
(N = 314) (% 
Matched) Gender 
*Distance to 
MDR 
hospital 
(km) 
Median 
delay in 
initiation of 
treatment 
(IQ range) 
(days) 
             Male (N = 191) Female (N = 123)   
Berea 70 (13.5) 44 (63.0) 19 25 63.2 12 (8-18) 
Butha Buthe 44 (8.5) 26 (59.1) 19 7 123.3 11 (7-14) 
Leribe 82 (15.4) 58 (71.0) 30 28 95.0 11 (7-14) 
Mafeteng 37 (7.1) 20 (54.1) 13 7 77.6 15 (10-24) 
Maseru 172 (33.2) 93 (54.1) 58 35 0 14 (9-25) 
Mohale’s Hoek 53 (10.2) 34 (64.2) 26 8 124.4 8 (7-10) 
Mokhotlong 4 (0.8) 2 (50.0) 1 1 292.4 6.5 (5-8) 
Qacha’s Nek 32 (6.2) 18 (56.1) 11 7 225.7 10 (8-19 
Quthing 11 (2.1) 9 (82.0) 6 3 175.1 16 (9-23) 
Thaba Tseka 13 (2.5) 10 (77.0) 8 2 176.3 60 (22-70) 
Over-all      12 (7-19) 
 413 
*Approximate distance, from patient district to the district where the MDR hospital is located.414 
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Table 3. Routinely collected phenotypic drug susceptibility testing results (Patients Diagnosed 415 
with RR-TB using GeneXpert) 416 
Phenotypic DST Resistance Profile* Number Percentage 
First-line DST (N = 101) Negative culture 7 6.9 
 R 34 33.7 
 H 2 2.0 
 RH 46 45.5 
 RHE 6 5.9 
 RS 1 1.0 
 RHS 2 2.0 
 RHES 3 3.0 
Second-line DST (N = 81) Negative culture 75 92.5 
 FQ 6 7.5 
 417 
*R: rifampicin resistance, H: isoniazid resistance, RH: rifampicin and isoniazid resistance, RHE: 418 
rifampicin, isoniazid and ethambutol resistance, RS: rifampicin and streptomycin resistance, 419 
RHS: rifampicin, isoniazid and streptomycin resistance, RHES: rifampicin, isoniazid, ethambutol 420 
and streptomycin resistance, FQ: fluoroquinolone resistance. DST: drug susceptibility test. 421 
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